.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,060,828

« Back to Dashboard

Details for Patent: 7,060,828

Title:Liposomal camptothecins and uses thereof
Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.
Inventor(s): Madden; Thomas D. (Vancouver, CA), Semple; Sean C. (Vancouver, CA)
Assignee: Inex Pharmaceuticals Corporation (Burnaby, CA)
Filing Date:Jun 29, 2001
Application Number:09/896,811
Claims:1. A liposomal topotecan unit dosage form, said unit dosage form comprising: a lipid; and a topotecan dosage of 0.01 mg/M.sup.2/dose to 7.5 mg/M.sup.2/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by weight of 0.05 to 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

2. A method of treating solid tumors in a mammal, said method comprising: administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising 0.01 mg/M.sup.2/dose to 7.5 mg/M.sup.2/dose of topotecan for an interval regime, wherein said liposomal topotecan formulation has a drug:lipid ratio by weight of 0.05 to 0.2 and wherein said liposome comprises a mixture of sphingomyelin and cholesterol for a time and under conditions effective to reduce and/or delay growth of the solid tumor mass.

3. The method of treating solid tumors of claim 2, wherein said interval regime is at least once a week.

4. The method of treating solid tumors of claim 2, wherein said interval regime is at least once every two weeks.

5. The method of treating solid tumors of claim 2, wherein said interval regime is at least once every three weeks.

6. The method of treating solid tumors of claim 2, wherein said interval regime is once a day for at least two consecutive days.

7. A liposomal camptothecin unit dosage form, said unit dosage form comprising a lipid, a camptothecin dosage of from 0.015 mg/M.sup.2/dose to 1 mg/M.sup.2/dose and having a drug:lipid ratio by weight of 0.05 to 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

8. The liposomal topotecan unit dosage form of claim 1, wherein said drug:lipid ratio by weight is 0.05 to 0.15.

9. The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises sphingomyelin and cholesterol in a molar ratio of 70:30 to 40:45.

10. The liposomal topotecan unit dosage form of claim 1, comprising from 1 mg/M.sup.2/dose to 4 mg/M.sup.2/dose of topotecan.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc